186 related articles for article (PubMed ID: 35932175)
41. Preclinical safety profile of disitamab vedotin:a novel anti-HER2 antibody conjugated with MMAE.
Jiang J; Li S; Shan X; Wang L; Ma J; Huang M; Dong L; Chen F
Toxicol Lett; 2020 May; 324():30-37. PubMed ID: 31877330
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.
Shemesh CS; Agarwal P; Lu T; Lee C; Dere RC; Li X; Li C; Jin JY; Girish S; Miles D; Lu D
Cancer Chemother Pharmacol; 2020 May; 85(5):831-842. PubMed ID: 32222808
[TBL] [Abstract][Full Text] [Related]
43. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
Garg A; Quartino A; Li J; Jin J; Wada DR; Li H; Cortés J; McNally V; Ross G; Visich J; Lum B
Cancer Chemother Pharmacol; 2014 Oct; 74(4):819-29. PubMed ID: 25119184
[TBL] [Abstract][Full Text] [Related]
44. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
[TBL] [Abstract][Full Text] [Related]
45. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
[TBL] [Abstract][Full Text] [Related]
46. A "Dual" Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC.
Singh AP; Shah DK
J Pharm Sci; 2019 Jul; 108(7):2465-2475. PubMed ID: 30790581
[TBL] [Abstract][Full Text] [Related]
47. A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
Cleary JM; Calvo E; Moreno V; Juric D; Shapiro GI; Vanderwal CA; Hu B; Gifford M; Barch D; Roberts-Rapp L; Ansell PJ; Xiong H; Ocampo C; Tolcher AW
Invest New Drugs; 2020 Oct; 38(5):1483-1494. PubMed ID: 32189093
[TBL] [Abstract][Full Text] [Related]
48. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
[TBL] [Abstract][Full Text] [Related]
49. Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery.
Li L; Xu MZ; Wang L; Jiang J; Dong LH; Chen F; Dong K; Song HF
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12929-12937. PubMed ID: 33378043
[TBL] [Abstract][Full Text] [Related]
50. Cathepsin B Cleavage of vcMMAE-Based Antibody-Drug Conjugate Is Not Drug Location or Monoclonal Antibody Carrier Specific.
Gikanga B; Adeniji NS; Patapoff TW; Chih HW; Yi L
Bioconjug Chem; 2016 Apr; 27(4):1040-9. PubMed ID: 26914498
[TBL] [Abstract][Full Text] [Related]
51. Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model-Informed Hypothesis Generation for Pediatric Dosing Regimens.
Suri A; Mould DR; Song G; Kinley J; Venkatakrishnan K
J Clin Pharmacol; 2020 Dec; 60(12):1585-1597. PubMed ID: 32596842
[TBL] [Abstract][Full Text] [Related]
52. Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy.
Best RL; LaPointe NE; Azarenko O; Miller H; Genualdi C; Chih S; Shen BQ; Jordan MA; Wilson L; Feinstein SC; Stagg NJ
Toxicol Appl Pharmacol; 2021 Jun; 421():115534. PubMed ID: 33852878
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells.
Sharma S; Li Z; Bussing D; Shah DK
Drug Metab Dispos; 2020 May; 48(5):368-377. PubMed ID: 32086295
[TBL] [Abstract][Full Text] [Related]
54. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
[TBL] [Abstract][Full Text] [Related]
55. Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and
Singh AP; Seigel GM; Guo L; Verma A; Wong GG; Cheng HP; Shah DK
J Pharmacol Exp Ther; 2020 Jul; 374(1):184-199. PubMed ID: 32273304
[TBL] [Abstract][Full Text] [Related]
56. Liquid chromatography-high resolution mass spectrometric method for the quantification of monomethyl auristatin E (MMAE) and its preclinical pharmacokinetics.
Lee BI; Park MH; Choi J; Shin SH; Byeon JJ; Park Y; Shin YG
Biomed Chromatogr; 2020 Aug; 34(8):e4855. PubMed ID: 32304111
[TBL] [Abstract][Full Text] [Related]
57. An Antibody-Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy.
Bakema JE; Stigter-van Walsum M; Harris JR; Ganzevles SH; Muthuswamy A; Houtkamp M; Plantinga TS; Bloemena E; Brakenhoff RH; Breij ECW; van de Ven R
Mol Cancer Ther; 2024 Feb; 23(2):187-198. PubMed ID: 37828725
[TBL] [Abstract][Full Text] [Related]
58. Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials.
Xiang H; Liu L; Gao Y; Ahene A; Collins H
Cancer Chemother Pharmacol; 2021 Nov; 88(5):899-910. PubMed ID: 34383128
[TBL] [Abstract][Full Text] [Related]
59. An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR.
Mittapalli RK; Stodtmann S; Friedel A; Menon RM; Bain E; Mensing S; Xiong H
J Clin Pharmacol; 2019 Sep; 59(9):1225-1235. PubMed ID: 30990907
[TBL] [Abstract][Full Text] [Related]
60. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
Liu JF; Moore KN; Birrer MJ; Berlin S; Matulonis UA; Infante JR; Wolpin B; Poon KA; Firestein R; Xu J; Kahn R; Wang Y; Wood K; Darbonne WC; Lackner MR; Kelley SK; Lu X; Choi YJ; Maslyar D; Humke EW; Burris HA
Ann Oncol; 2016 Nov; 27(11):2124-2130. PubMed ID: 27793850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]